TAK Stock Recent News
TAK LATEST HEADLINES
High-yield dividend stocks can be great additions to a long-term-oriented portfolio. Takeda Pharmaceutical and AT&T screen as two of the most attractive buys in the high-yield space right now.
Christophe Weber, CEO of Takeda, says there are some setbacks in research and development, but most of those drugs should fuel the company's growth in the future.
Takeda Pharmaceutical Co said on Tuesday it was voluntarily withdrawing its application for its dengue vaccine candidate, following discussions with the U.S. health regulator.
Takeda Pharmaceutical's stock has appreciated 10% since December, with economic and fundamental catalysts supporting a buy rating. TAK has shown strong growth in revenue and operating capital as well as promise in its pipeline and geographic diversification. A valuation of $41.8 per share is potentially warranted, with a reiterated buy rating.
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2022 Results Conference Call May 11, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Global Head of IR & Global Finance Christophe Weber - President, CEO & Representative Director Andrew Plump - President of Research & Development and Representative Director Constantine Saroukos - CFO & Representative Director Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business Unit Ramona Sequeira - President of Global Portfolio Division Conference Call Participants Yamaguchi-san - Citigroup Tony Ren - Macquarie Mamegano-san - BofA Securities Muraoka-san - Morgan Stanley Michael Nedelcovych - TD Cowen Miki Sogi - Bernstein Christopher O'Reilly Thank you very much for joining FY 2022 earnings announcement of Takeda. I will serve as MC, Head of IR.
Sales of Takhzyro amounted to 44.1 billion Japanese yen in the 3rd quarter of 2022, an increase of 42.7% from the previous year. Takeda Pharmaceutical's revenue was $8,354 million in Q3 2022, showing phenomenal growth both year-on-year and quarter-on-quarter.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Takeda's late-stage pipeline is impressive with many candidates boasting very strong fundamentals. Technically though, shares are now coming up against significant overhead resistance.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2023 Earnings Conference Call February 2, 2023 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Andy Plump - President, R&D Costa Saroukos - Chief Financial Officer Ramona Sequeira - President, Global Portfolio Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Motoya Koutani - Nomura Securities Seiji Wakao - JPMorgan Shinichiro Muraoka - Morgan Stanley Christopher O'Reilly Thank you for taking time out of your very busy schedule to join us for the FY ‘22 Q3 Earnings Announcement by Takeda. My name is O'Reilly, Head of IR.